Back

Comparing the Cost-Effectiveness of Alternative Policies for Recommending and Providing HIV Pre-exposure Prophylaxis to Men Who Have Sex With Men in the EU

WANG, B.; Brazia, J.; Teixeira, A. S.; Valdano, E.

2025-01-28 health economics
10.1101/2025.01.28.25321249 medRxiv
Show abstract

BackgroundIn the European Union (EU), HIV disproportionately affects men who have sex with men (MSM), with prevalence rates ranging from 2.4% to 29%. Despite the high efficacy of pre-exposure prophylaxis (PrEP) in preventing HIV, its accessibility and uptake remain uneven across countries. This study examines the effectiveness and cost-effectiveness of different PrEP policies across 20 EU countries. MethodsWe employed a stochastic agent-based model of HIV transmission among MSM. The model incorporated data on sexual behavior, PrEP adherence and healthcare costs to evaluate the impact of five distinct PrEP eligibility policies. Outcomes included HIV infections averted, HIV-related deaths prevented, PrEP coverage, and incremental cost-effectiveness ratio. FindingsPolicies by the US, CDC, and Belgian authorities were the most effective in reducing HIV infections and deaths, driven by higher PrEP coverage. However, the WHO policy emerged as the most cost-effective across the 20 countries, despite its current use being limited to Denmark. The European AIDS Clinical Society guidelines also showed potential, although not currently implemented. In countries without PrEP reimbursement, reducing drug costs would significantly expand the range of cost-effective policy options. InterpretationOptimizing PrEP policies is crucial for reducing HIV incidence among MSM in the EU. Broad eligibility criteria maximize effectiveness, while WHO guidelines offer a cost-effective alternative in constrained economic contexts. Our findings highlight the need for policy adjustments to enhance PrEP accessibility, inform national health strategies, and achieve sustainable HIV prevention across diverse settings. FundingCampus France PHC Pessoa, French Government; Portugal-France Bilateral Co-operation 2022 Programa Pessoa ref. 2022.15068.CBM; FCT -- Fundacao para a Ciencia e Tecnologia -- through the LASIGE Research Unit, ref. UIDB/00408/2020 and ref. UIDP/00408/2020; Horizon Europe grant SIESTA (101131957).

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
AIDS
31 papers in training set
Top 0.1%
22.0%
2
BMJ Open
554 papers in training set
Top 2%
9.8%
3
PLOS ONE
4510 papers in training set
Top 23%
8.2%
4
JAIDS Journal of Acquired Immune Deficiency Syndromes
19 papers in training set
Top 0.1%
6.2%
5
PLOS Medicine
98 papers in training set
Top 0.5%
6.2%
50% of probability mass above
6
BMC Health Services Research
42 papers in training set
Top 0.4%
4.7%
7
BMJ Global Health
98 papers in training set
Top 0.8%
3.9%
8
BMC Medicine
163 papers in training set
Top 1%
3.6%
9
Clinical Infectious Diseases
231 papers in training set
Top 2%
3.5%
10
The Lancet Global Health
24 papers in training set
Top 0.4%
3.5%
11
The Lancet Infectious Diseases
71 papers in training set
Top 0.9%
3.2%
12
Medical Decision Making
10 papers in training set
Top 0.1%
2.7%
13
American Journal of Preventive Medicine
11 papers in training set
Top 0.2%
1.8%
14
BMC Public Health
147 papers in training set
Top 3%
1.8%
15
Addiction
25 papers in training set
Top 0.3%
1.7%
16
Nature Human Behaviour
85 papers in training set
Top 3%
1.3%
17
PLOS Global Public Health
293 papers in training set
Top 4%
1.3%
18
BMJ Public Health
18 papers in training set
Top 0.4%
1.2%
19
eClinicalMedicine
55 papers in training set
Top 2%
0.7%
20
International Journal of Cancer
42 papers in training set
Top 1%
0.7%
21
American Journal of Epidemiology
57 papers in training set
Top 2%
0.7%
22
Epidemiology
26 papers in training set
Top 0.7%
0.6%
23
Vaccine
189 papers in training set
Top 2%
0.6%